at the population level in patients with HFrEF eligible for SGLT2 inhibitor treatment, lead to an estimated relative risk reduction in all-cause mortality of 73%. 15 Authors of the guideline call ...
The new approach is designed to create a connection between the left and right atrial chambers of the heart in a single ...
BiovitalsHF uses software algorithms and wearable sensors to help direct drug treatment for HFrEF, encourage patients ... It has been designed to follow guideline-directed medical therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback